Wedbush analyst Laura Chico maintained a Buy rating on Solid Biosciences (SLDB – Research Report) yesterday and set a price target of $17.00. The company’s shares closed yesterday at $2.77.

According to TipRanks, Chico is a 3-star analyst with an average return of 1.3% and a 43.10% success rate. Chico covers the Healthcare sector, focusing on stocks such as Travere Therapeutics, Astria Therapeutics, and Biogen.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Solid Biosciences with a $16.00 average price target.

Based on Solid Biosciences’ latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $39.28 million. In comparison, last year the company had a GAAP net loss of $24.3 million

Based on the recent corporate insider activity of 23 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of SLDB in relation to earlier this year. Most recently, in March 2025, Kahn Clare, a Director at SLDB bought 1,860.00 shares for a total of $9,913.80.